Steglatro

Steglatro contains ertugliflozin, an inhibitor of the sodium-glucose co-transporter 2 (SGLT2). SGLT2 is the primary transporter responsible for reabsorbing glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion and lowering blood glucose levels.

Dosage by Body Weight

The recommended starting dose of Steglatro is 5 mg once daily in the morning, taken with or without food. In patients tolerating Steglatro 5 mg once daily who require additional glycemic control, the dose may be increased to 15 mg once daily. Assess renal function prior to initiation and periodically thereafter.

Body Weight
Below 5 kg
Dose
Not recommended
Frequency
N/A
Tracking Notes
Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.
Body Weight
5-7 kg
Dose
Not recommended
Frequency
N/A
Tracking Notes
Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.
Body Weight
8-10 kg
Dose
Not recommended
Frequency
N/A
Tracking Notes
Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.
Body Weight
11-15 kg
Dose
Not recommended
Frequency
N/A
Tracking Notes
Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.
Body Weight
16-20 kg
Dose
Not recommended
Frequency
N/A
Tracking Notes
Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.

Weight-based dosage tracking table for Steglatro, including body weight, dose, frequency, and tracking notes.
Body Weight	Dose	Frequency	Tracking Notes
Below 5 kg	Not recommended	N/A	Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.
5-7 kg	Not recommended	N/A	Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.
8-10 kg	Not recommended	N/A	Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.
11-15 kg	Not recommended	N/A	Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.
16-20 kg	Not recommended	N/A	Safety and effectiveness of Steglatro in pediatric patients under 18 years of age have not been established.

Formulation

Tablet

Purpose

Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Generic Name

Ertugliflozin

Scheduled Drug

No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.

Alternatives

Jardiance Farxiga Invokana